CAJ | 학술논문

采用乳剂制备技术与微囊制备技术相结合的方法，以甲基纤维素和可溶性淀粉为囊材，制备了恩诺沙星微囊。结果表明，制备的恩诺沙星微囊分散状态良好，平均粒径为47．6μm，粒径分布在20μm～70μm 范围内的微囊占88％，载药量为12．5％±0．40％，具有一定的缓释作用。急性毒性试验结果显示恩诺沙星微囊的 LD50为5968．81 mg／kg，95％可信限为5164．06 mg／kg～6978．86 mg／kg，表明恩诺沙星微囊毒性很低，可以进行药效学试验研究。
채용유제제비기술여미낭제비기술상결합적방법，이갑기섬유소화가용성정분위낭재，제비료은낙사성미낭。결과표명，제비적은낙사성미낭분산상태량호，평균립경위47．6μm，립경분포재20μm～70μm 범위내적미낭점88％，재약량위12．5％±0．40％，구유일정적완석작용。급성독성시험결과현시은낙사성미낭적 LD50위5968．81 mg／kg，95％가신한위5164．06 mg／kg～6978．86 mg／kg，표명은낙사성미낭독성흔저，가이진행약효학시험연구。
By combining drug emulsion preparation technique and microcapsule preparation method,enro-floxacin microcapsules enveloped by methyl cellulose and soluble starch were prepared.The results showed that enrofloxacin microcapsule dispersed well,and the average particle diameter was 47.6 μm with 88% of the microcapsules ranging from 20 μm to 70 μm.The microcapsules had a certain sustained release effect and the drug loading was 12.5%±0.40%.The acute toxicity tests showed that the LD50 for enrofloxacin microencapsulation was 5 968.81 mg/kg,95% confidence limit was 5 164.06 mg/kg to 6 978.86 mg/kg. It is concluded that the enrofloxacin microcapsule is safety,and can be used in clinical trials.